Virtual visit appointments available 7 days a week from 9:00am to 11:00pm. Learn More
Texas Medical Center
1102 Bates Ave., Ste. 1570
Houston, TX 77030
Lisa L. Wang, MD
Director, Bone Tumors Program
Clinical Leader, Musculoskeletal Tumor Clinic
Associate Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
|Baylor College of Medicine||Fellowship||Pediatric Hematology/Oncology||2001|
|Children's Hospital of Los Angeles||Residency||Pediatrics||1996|
|University of North Carolina at Chapel Hill||Medical School||Doctor of Medicine||1993|
|Washington University School of Medicine||Bachelors||Bachelor of Arts||1988|
Dr. Lisa Wang is Director of the Bone Tumor Program and the Clinical Leader of the Musculoskeletal Tumor Clinic at Texas Children's Cancer Center.
Dr. Wang has a special interest in sarcomas, particularly bone sarcomas such as osteosarcoma and Ewing's sarcoma.
The Musculoskeletal Tumor Clinic is an interdisciplinary clinic within the outpatient clinic at Texas Children's Cancer Center that brings together a team of clinical specialists who take care of patients with a variety of bone tumors. The team includes pediatric oncologists, orthopedic surgeon, physical therapist, social worker, among other caregivers.
Dr. Wang is certified by the American Board of Pediatrics in pediatric hematology/oncology.
|American Association for Cancer Research (AACR)||Member|
|American Society of Clinical Oncology (ASCO)||Member|
|American Society of Human Genetics||Member|
|American Society of Pediatric Hematology/Oncology (ASPHO)||Member|
|Children's Oncology Group (COG)||Member|
Dr. Lisa Wang’s research interests focus on the molecular pathogenesis of osteosarcoma. She specifically focuses on the RECQL4 pathway and Rothmund-Thomson syndrome (RTS), a rare, inherited disorder that predisposes affected individuals to developing osteosarcoma.
Her research goals include:
- understanding the molecular basis of Rothmund-Thomson syndrome and related disorders by studying the mechanisms that predispose individuals to cancer development;
- defining the clinical phenotype and appropriate medical management of these patients; and
- understanding the role of RECQL4 pathways in the pathogenesis of osteosarcoma and skeletal development.
Her lab has established an international registry of RTS patients and families.
The Future of Osteosarcoma and Other Pediatric Bone Tumors
* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.